A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.


West, SK; Bailey, R; Munoz, B; Edwards, T; Mkocha, H; Gaydos, C; Lietman, T; Porco, T; Mabey, D; Quinn, TC; (2013) A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. PLoS neglected tropical diseases, 7 (8). e2415. ISSN 1935-2727 DOI: https://doi.org/10.1371/journal.pntd.0002415

[img]
Preview
Text - Published Version
License:

Download (773kB) | Preview

Abstract

BACKGROUND The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is >10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at children with multiple rounds is unknown. TRIAL DESIGN 2×2 factorial community randomized, double blind, trial. TRIAL METHODS 32 communities with prevalence of trachoma ≥20% were randomized to: annual MDA aiming for coverage of children between 80%-90% (usual target) versus aiming for coverage>90% (enhanced target); and to: MDA for three years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%. The primary outcome was the community prevalence of infection with C. trachomatis at 36 months. RESULTS Over the trial's course, no community met the MDA cessation rule, so all communities had the full 3 rounds of MDA. At 36 months, there was no significant difference in the prevalence of infection, 4.0 versus 5.4 (mean adjusted difference = 1.4%, 95% CI = -1.0% to 3.8%), nor in the prevalence of trachoma, 6.1 versus 9.0 (mean adjusted difference = 2.6%, 95% CI = -0.3% to 5.3%) comparing the usual target to the enhanced target group. There was no difference if analyzed using coverage as a continuous variable. CONCLUSION In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage. Increasing coverage in children above 90% does not appear to confer additional benefit.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Tropical Epidemiology Group
PubMed ID: 24009792
Web of Science ID: 323941500061
URI: http://researchonline.lshtm.ac.uk/id/eprint/1229331

Statistics


Download activity - last 12 months
Downloads since deposit
174Downloads
352Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item